论文部分内容阅读
目的探讨非比麸(小麦纤维素颗粒)和培菲康(双歧杆菌三联活菌散)联合治疗儿童功能性便秘(FC)的效果和安全性。方法选择2009年1月-2011年3月在深圳市福田区幼儿园、小学调查和本院门诊FC患儿98例,随机分为3组:非比麸+培菲康治疗组36例(联合组)、非比麸治疗组32例(非比麸组)和对照组30例。对照组予基础治疗,包括调整饮食、训练排便方法、适量饮水、适量运动;联合组在基础治疗上加服非比麸和培菲康;非比麸在基础治疗上加服非比麸,疗程2周。根据患儿大便次数、性状及临床情况综合判断疗效,停药2周和4周根据大便次数和性状判断复发率,比较3组治疗有效率和复发率。结果 1.治疗2周,联合组总有效率为91.67%,显著高于非比麸(68.75%)和对照组(43.33%)(Pa<0.05,0.01);非比麸总有效率明显高于对照组(P<0.05)。2.停药2周,联合组、非比麸及对照组复发率分别为5.56%、21.88%和30%,联合组复发率显著低于对照组(P<0.05);停药4周,联合组、非比麸、对照组复发率分别为16.67%、40.63%和46.67%,联合组复发率显著低于非比麸和对照组(Pa<0.05)。未见药物不良反应。结论非比麸和培菲康联合治疗儿童FC疗效显著、安全,且复发率低。
Objective To investigate the efficacy and safety of combination of non-specific bran (wheat cellulose granules) and Pefikan (Bifidobacterium triple viable) in the treatment of children with functional constipation (FC). Methods From January 2009 to March 2011, 98 children with FC in kindergarten and primary school of Futian District, Shenzhen were randomly divided into 3 groups: 36 cases of non-bran + Peifukang treatment group (combination group ), 32 cases of non-bran than non-bran group and 30 cases of control group. The control group was given basic treatment, including diet adjustment, defecation training method, moderate amount of drinking water and moderate exercise. The combination group added non-bran and pefloxacin to the basic treatment, while the non-bran added non-bran on the basic treatment. 2 weeks. According to the stool frequency, traits and clinical conditions in children comprehensive judgment of efficacy, withdrawal 2 weeks and 4 weeks according to stool frequency and traits to determine the recurrence rate, treatment efficiency and recurrence rate of the three groups were compared. The total effective rate in the combined group was 91.67%, significantly higher than that in the non-specific bran (68.75%) and the control group (43.33%) (Pa, 0.05, 0.01) Control group (P <0.05). The relapse rates in combination group, non-specific bran group and control group were 5.56%, 21.88% and 30%, respectively. The relapse rate in combination group was significantly lower than that in control group (P <0.05) The recurrence rates were 16.67%, 40.63% and 46.67% in the control group, non-specific bran group and control group, respectively. The recurrence rate in the combined group was significantly lower than that in the non-specific glucosidic group and the control group (Pa0.05). No adverse drug reactions. Conclusion The combination therapy of non-specific bran and Pefikon in children with FC has significant effect, safety and low recurrence rate.